This section is intended for UK healthcare professionals. If you are a member of the public click here. If you have been prescribed ADCETRIS click here.

ADCETRIS provides a step change in treatment for Relapsed/Refractory Hodgkin lymphoma (R/R HL) and Relapsed/Refractory systemic
Anaplastic Large Cell Lymphoma (R/R sALCL)1

Indications

ADCETRIS is indicated for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin Lymphoma:2

1. following autologous stem cell transplant (ASCT) or

2. following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option

ADCETRIS is indicated for the treatment of adult patients with CD30+ HL at increased risk of relapse or progression following ASCT.2

ADCETRIS is indicated for the treatment of adult patients with relapsed or refractory systemic Anaplastic Large Cell Lymphoma (sALCL).2

Patient Support

Takeda Oncology has developed a range of information and support tools designed for patients prescribed ADCETRIS

View patient support materials

Patient Support Booklet, PN Diary, PN Leaflet

Adverse events should be reported. In the United Kingdom, reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.

Adverse events should also be reported to Takeda on 01628 537900 or e-mail DSO-UK@takeda.com.